Transthyretin Amyloid Cardiomyopathy Treatment Market Size to Exceed USD 19.37 Bn by 2032

The Transthyretin Amyloid Cardiomyopathy Treatment Market, estimated at USD 2.91 Bn in 2025, is expected to exhibit a CAGR of 31.1% and reach USD 19.37 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Increasing research and development by key market players on transthyretin amyloid cardiomyopathy (ATTR-CM) treatment isexpected to drive the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth over the forecast period.Increasing understanding of this diseaseleads to increase in clinical trials and studies focused on developing more effective therapies. Investigational drugs, gene-silencing therapies, and novel approaches aims to target the root cause of ATTR-CM such as the abnormal accumulation of transthyretin proteins. For instance, in November 2020, Intellia Therapeutics, a clinical-stage biotechnology company, initiated a phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with polyneuropathy and participants with hereditary transthyretin amyloidosis with cardiomyopathy or wild type cardiomyopathy. These efforts are driven by the increasing need to find better treatment options for this life-threatening disease, providing hope for patients and their families, and potentially transforming the landscape of ATTR-CM management. The increasing research underscores the urgency of addressing this complex medical challenge.

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and has a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

The COVID-19 pandemic had a negative impact on the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. The prioritization of healthcare resources and the shift in focus towards managing the pandemic significantly affected the diagnosis and treatment of ATTR-CM. Many non-urgent medical procedures were postponed, and thus, leading to delayed diagnoses and treatment initiation for ATTR-CM patients.  The economic strain caused by the pandemic  hindered patient’s access to expensive ATTR-CM therapies. Furthermore, the pharmaceutical industry faced supply chain disruptions and research delays, thus, impacting the development of new ATTR-CM treatments.

However, the pandemic also accelerated the adoption of telemedicine and remote monitoring solutions, thus, potentially improving patient management for ATTR-CM in the long term.          

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market: Key Developments

On October 09, 2023, Alnylam Pharmaceuticals, a U.S.-based biopharmaceutical company,  announced that its application was rejected by the U.S. Food and Drug Administration (U.S FDA) to expand the use of Onpattro for ATTR-CM, or transthyretin-mediated amyloidosis with cardiomyopathy, citing a lack of clinically significant data.

In July 2023, BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, reported positive results from its study: ATTRibute-CM which is a Phase 3 study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM.

In July 2023, Ionis Pharmaceuticals, Inc., a U.S.-based a biotechnology company, announced the completion of enrollment in its Phase 3 CARDIO-TTRansform cardiovascular outcomes study. The study evaluates efficacy of eplontersen in treating patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Browse 35 Market Data Tables and 31 Figures spread through 180 Pages and in-depth TOC on “Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR) and Wild Type Transthyretin Amyloidosis (wtATTR)), By Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)  

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/transthyretin-amyloid-cardiomyopathy-treatment-market-4321

Key Takeaways of the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market:

• Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is expected to exhibit a CAGR of 31.1% during the forecast period. Increasing awareness about ATTR-CM due to initiatives by key market players is expected to drive the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth over the forecast period. For instance, in February 2023, Pfizer Inc, a multinational pharmaceutical company, announced partnership with nationwide community organizations in the  S. to raise awareness about ATTR-CM.
• Among drug type, the transthyretin stabilizers segment is expected to hold a dominant position in the market during the forecast period due to increasing adoption of strategic partnerships by key market players. For instance, in July 2023, Ionis Pharmaceuticals, Inc., a U.S.-based a biotechnology company, announced that it hadexpanded its existing partnership with AstraZeneca, a multinational pharmaceutical and biotechnology company, to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin America.
• Among region, North America is expected to be the dominant region in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market over the forecast period, owing to the high concentration of market players like Pfizer Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals etc. in the region.
• Major players operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.